Gliquidone: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|An oral hypoglycemic agent used in the management of type 2 diabetes mellitus}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Gliquidone.svg | |||
| image2 = <!-- Another image if available --> | |||
}} | |||
'''Gliquidone''' is an oral [[hypoglycemic agent]] belonging to the class of [[sulfonylureas]]. It is primarily used in the management of [[type 2 diabetes mellitus]]. Gliquidone works by stimulating the release of [[insulin]] from the [[beta cells]] of the [[pancreas]]. | |||
==Pharmacology== | ==Pharmacology== | ||
Gliquidone | Gliquidone is a second-generation sulfonylurea. It binds to the sulfonylurea receptor on the beta cells, leading to the closure of [[ATP-sensitive potassium channels]]. This action results in the depolarization of the cell membrane and the opening of [[voltage-gated calcium channels]], which increases intracellular calcium concentration and stimulates insulin secretion. | ||
== | ==Clinical use== | ||
Gliquidone is indicated for the treatment of | Gliquidone is indicated for the treatment of type 2 diabetes mellitus in patients who cannot achieve adequate glycemic control with [[diet]] and [[exercise]] alone. It is particularly useful in patients with [[renal impairment]] as it is primarily metabolized by the [[liver]] and excreted in the [[bile]]. | ||
==Side | ==Side effects== | ||
Common side effects of | Common side effects of gliquidone include [[hypoglycemia]], [[weight gain]], and [[gastrointestinal disturbances]] such as [[nausea]] and [[diarrhea]]. Rarely, it may cause [[allergic reactions]] or [[hematological disorders]]. | ||
==Contraindications== | ==Contraindications== | ||
Gliquidone is contraindicated in patients with [[ | Gliquidone is contraindicated in patients with [[type 1 diabetes mellitus]], [[diabetic ketoacidosis]], and those with known hypersensitivity to sulfonylureas. Caution is advised in patients with [[hepatic impairment]]. | ||
==Related | ==Mechanism of action== | ||
* [[ | [[File:Gliquidone.svg|thumb|right|Chemical structure of Gliquidone]] | ||
Gliquidone acts by binding to the sulfonylurea receptor on the pancreatic beta cells. This binding inhibits the efflux of potassium ions, leading to cell depolarization. The subsequent influx of calcium ions triggers the exocytosis of insulin-containing granules, thereby increasing insulin secretion. | |||
==Metabolism and excretion== | |||
Gliquidone is extensively metabolized in the liver to inactive metabolites. It is excreted primarily in the bile, making it suitable for use in patients with renal impairment. The drug has a relatively short half-life, which reduces the risk of prolonged hypoglycemia. | |||
==Related pages== | |||
* [[Type 2 diabetes mellitus]] | |||
* [[Sulfonylurea]] | |||
* [[Insulin]] | * [[Insulin]] | ||
* [[Hypoglycemia]] | * [[Hypoglycemia]] | ||
[[Category:Sulfonylureas]] | |||
[[Category:Antidiabetic drugs]] | |||
Latest revision as of 04:04, 13 February 2025
An oral hypoglycemic agent used in the management of type 2 diabetes mellitus
| Gliquidone | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Gliquidone is an oral hypoglycemic agent belonging to the class of sulfonylureas. It is primarily used in the management of type 2 diabetes mellitus. Gliquidone works by stimulating the release of insulin from the beta cells of the pancreas.
Pharmacology[edit]
Gliquidone is a second-generation sulfonylurea. It binds to the sulfonylurea receptor on the beta cells, leading to the closure of ATP-sensitive potassium channels. This action results in the depolarization of the cell membrane and the opening of voltage-gated calcium channels, which increases intracellular calcium concentration and stimulates insulin secretion.
Clinical use[edit]
Gliquidone is indicated for the treatment of type 2 diabetes mellitus in patients who cannot achieve adequate glycemic control with diet and exercise alone. It is particularly useful in patients with renal impairment as it is primarily metabolized by the liver and excreted in the bile.
Side effects[edit]
Common side effects of gliquidone include hypoglycemia, weight gain, and gastrointestinal disturbances such as nausea and diarrhea. Rarely, it may cause allergic reactions or hematological disorders.
Contraindications[edit]
Gliquidone is contraindicated in patients with type 1 diabetes mellitus, diabetic ketoacidosis, and those with known hypersensitivity to sulfonylureas. Caution is advised in patients with hepatic impairment.
Mechanism of action[edit]
Gliquidone acts by binding to the sulfonylurea receptor on the pancreatic beta cells. This binding inhibits the efflux of potassium ions, leading to cell depolarization. The subsequent influx of calcium ions triggers the exocytosis of insulin-containing granules, thereby increasing insulin secretion.
Metabolism and excretion[edit]
Gliquidone is extensively metabolized in the liver to inactive metabolites. It is excreted primarily in the bile, making it suitable for use in patients with renal impairment. The drug has a relatively short half-life, which reduces the risk of prolonged hypoglycemia.
